VYEPTI is indicated for the preventive treatment of migraine in adults. View patient site
VYEPTI is indicated for the preventive treatment of migraine in adults.

VYEPTI is administered as an IV infusion every 3 months1

Vials icon

VYEPTI is approved for 100 mg and 300 mg doses1

100 mg is the recommended dose. Some patients may benefit from the approved 300 mg dose.

Infusion location options icon

VYEPTI can be given at an infusion location or at home

Use the VYEPTI Infusion Locator to help your patients find a convenient location to get their 30-minute VYEPTI treatment.

For details and support on administering VYEPTI, download the guide and watch the short video.

Some patients may have payer-mandated or in-network infusion sites.

Chanci was compensated for her time.

IV infusion bag icon

Learn more about VYEPTI administration

VYEPTI infusion guide thumbnail

VYEPTI dosing and administration guide

Get step-by-step instructions for administering VYEPTI, dilution instructions, and frequently asked questions.

DOWNLOAD THE GUIDE

VYEPTI dosing and administration video

Step-by-step instructions for the preparation and administration of VYEPTI.

TEST
VYEPTI Dosing and Administration Video
Real VYEPTI experience icon

Hear firsthand about VYEPTI infusions

Meet Stephanie, a real VYEPTI patient

"I wasn't nervous about doing IV treatments because I've had other IV treatments in my lifetime."

WATCH THE VIDEO

Stephanie was compensated for her time.

Patient results may vary.

Meet Stephanie, a real VYEPTI patient

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

Reference:

  1. VYEPTI (eptinezumab-jjmr) [package insert]. Bothell, WA: Lundbeck Seattle BioPharmaceuticals, Inc.
Site map Terms of Use Privacy Policy Contact us Cookie settings

© 2024 Lundbeck. All rights reserved. VYEPTI and VYEPTI GO are registered trademarks, and VYEPTI CONNECT is a trademark of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-101196v4

All trademarks, logos, and brand names are the property of their respective owners. All company, product, and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.

This website is intended for US healthcare professionals only.